Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Response to 'Re. Doppler Ultrasound Examination of Multiple Sclerosis Patients and Control Participants: Inter-observer Agreement and Association with Disease'
Interactions between Neutrophils, Th17 Cells, and Chemokines during the Initiation of Experimental Model of Multiple Sclerosis.
Diffusion abnormality in Balo's concentric sclerosis: clues for the pathogenesis.
Seroprevalence of NMO-IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis.
Myelin repair by transplantation of myelin-forming cells in globoid cell leukodystrophy.
Inhibition of β-oxidation is not a valid therapeutic tool for reducing oxidative stress in conditions of neurodegeneration.
A qualitative investigation of exercising with MS and the impact on the spousal relationship.
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.
[A young woman with central facial nerve palsy].
Characteristics of Patients With Relapsing Remitting Multiple Sclerosis Taking Once Daily Fingolimod Capsules In The United States.
Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.
Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis.
Multiple sclerosis in families: risk factors beyond known genetic polymorphisms.
Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ).
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity.
Electrical and Network Neuronal Properties Are Preferentially Disrupted in Dorsal, But Not Ventral, Medial Entorhinal Cortex in a Mouse Model of Tauopathy.
N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.
Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.
Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression
Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.
Catalpol induces oligodendrocyte precursor cell-mediated remyelination in vitro.
Celastrol and Its Role in Controlling Chronic Diseases.
Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis.
Genetics of rat neuroinflammation.

Pages